White Paper AGA: Optimal Strategies to Define and Diagnose Gastroesophageal Reflux Disease.
Division of Gastroenterology, Hepatology, and Nutrition, Vanderbilt University Medical Center, Nashville, Tennessee. Electronic address: michael.vaezi@vanderbilt.edu.
Michael F
MF
Vaezi
Division of Gastroenterology and Hepatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
John E
JE
Pandolfino
Division of Gastroenterology and Hepatology, Mayo Clinic, Scottsdale, Arizona.
Marcelo F
MF
Vela
Division of Gastroenterology & Hepatology, University of North Carolina School of Medicine, Chapel Hill, North Carolina.
Nicholas J
NJ
Shaheen
D001418:Baclofen / Q000627:therapeutic use; D001706:Biopsy; D016099:Endoscopy, Gastrointestinal; D050782:Esophageal pH Monitoring / Q000379:methods; D004941:Esophagitis / Q000145:classification; D004943:Esophagogastric Junction / Q000503:physiopathology; D004947:Esophagus / Q000473:pathology; D005764:Gastroesophageal Reflux / Q000175:diagnosis* / Q000628:therapy*; D006551:Hernia, Hiatal / Q000150:complications; D006801:Humans; D007828:Laryngoscopy; D008365:Manometry; D009125:Muscle Relaxants, Central / Q000627:therapeutic use; D000071066:Patient Reported Outcome Measures; D010641:Phenotype; D057285:Precision Medicine; D054328:Proton Pump Inhibitors / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D012720:Severity of Illness Index; D011795:Surveys and Questionnaires; D004561:Transcutaneous Electric Nerve Stimulation
D009125:Muscle Relaxants, Central; D054328:Proton Pump Inhibitors; D001418:Baclofen